logo
Twitter
Discord
Email
logo
Pharvaris N.V.

Pharvaris N.V.

NASDAQ•PHVS
CEO: Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-02-05
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Contact Information
Emmy Noetherweg 2, Leiden, 2333 BK, Netherlands
31-71-203-6410
pharvaris.com
Market Cap
$1.40B
P/E (TTM)
-6.1
45.5
Dividend Yield
--
52W High
$26.33
52W Low
$11.51
52W Range
69%
2.7
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q2 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.94+50.91%
4-Quarter Trend

FCF

-$33.99M+8.08%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Net Loss Widens Significantly Net Loss reached €134.22M in 2024, a 33% increase, reflecting substantial investment in R&D activities.
Operating Expenses Jump Fifty Percent Total operating expenses increased 50% to €145.69M in 2024, primarily due to €98.56M in R&D spending.
Clinical Data Supports Development Deucrictibant XR prophylaxis showed 84.5% attack rate reduction in Phase 2; Phase 3 trials are now initiated globally.
Cash Position Decreases Cash and equivalents ended 2024 at €280.73M, down 28% from prior year, due to high operating cash usage.

Risk Factors

Continued Losses Expected Limited operating history means no revenues; expects to incur losses for several future years before potential profitability.
Funding Needs Remain Substantial Requires substantial additional capital; inability to raise funds on acceptable terms risks delaying programs or insolvency.
Clinical Trial Uncertainty High Clinical setbacks, inconclusive results, or regulatory hurdles could materially affect business and development prospects.
Geopolitical Instability Risks Global events like conflicts in Ukraine and Middle East may disrupt ongoing clinical trials in affected European regions.

Outlook

Advance Phase 3 Clinical Trials Continue parallel development of IR (on-demand) and XR (prophylaxis) formulations through global pivotal Phase 3 studies.
Expect Key Phase 3 Readouts Anticipate topline data for RAPIDe-3 (IR) in Q1 2026 and CHAPTER-3 (XR) in the second half of 2026.
Expand Bradykinin Portfolio Leverage expertise to identify new indications beyond HAE, targeting cardiovascular, allergy, and immunology diseases.
Build Integrated Commercial Structure Intends to develop fully integrated sales and marketing organization ahead of potential marketing approval for products.

Peer Comparison

Revenue (TTM)

BioCryst Pharmaceuticals, Inc.BCRX
$599.82M
+45.4%
Zymeworks Inc.ZYME
$122.87M
+95.9%
Syndax Pharmaceuticals, Inc.SNDX
$111.55M
+574.6%

Gross Margin (Latest Quarter)

Atai Life Sciences N.V.ATAI
100.0%
+30.0 pp
Immunome, Inc.IMNM
100.0%
+0.0 pp
Zymeworks Inc.ZYME
100.0%
+13.1 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
BCRX$1.51B-171.71.9%0.0%
PHVS$1.40B-6.1-69.1%0.3%
SYRE$1.38B-53.1-31.2%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 7, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.68+5.7%
    N/A

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 10, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.84-15.9%
    N/A

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Apr 5, 2023|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.39-61.0%
    N/A

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 29, 2022|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.67-65.9%
    N/A

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Apr 29, 2021|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.97-240.0%
    N/A